In their study of the effects of chondroitin sulfate on glioma, zhu et al. found that this drug promoted CD44 degradation, inhibited integrin β1 expression in glioma cells and thereby slowed down the aggressiveness of glioma, indicating a non-negligible role of CD44 in glioma [34]. Here, CD44 is linked to central nervous system cancer.